Steven Aronowitz

Jan 9, 2025 | mckinsey.com | Brandon Parry |Lucy Perez |Steven Aronowitz

We are in a moment of vast potential in life sciences—of diversified investments, breakthrough discoveries, and rapid expansion of therapeutics into new modalities and platforms. And AI is increasingly enabling data-driven decision-making across the product life cycle, from AI-supported drug candidate selection to real-time clinical trial site monitoring. However, overall industry productivity—whether measured in terms of speed, cost-effectiveness, or ROI—has been stagnant for decades.